JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

GESTATIONAL DIABETES MELLITUS: WHAT ARE THE PREFERRED INSULIN REGIMENS? A REVIEW

M Kamran Khan, Firdous Shaikh
Nidan Kutir Diabetes Care and Research Centre, Bhagalpur
Jyoti polyclinic and diagnostic centre, Bandra west, Mumbai

Abstract
Pregnancies affected by diabetes carry significant dangers. By maintaining optimal blood sugar levels, many harmful effects for both the mother and baby can be prevented. While a majority of women with gestational diabetes mellitus (GDM) are able to manage their condition through approaches other than insulin—such as dietary modifications—there remains a substantial proportion who require insulin treatment alongside lifestyle interventions. Newer types of insulin, known as insulin analogs, offer clear benefits: they lower the chance of hypoglycemia, particularly at night, and more closely replicate the way natural insulin works in pregnant women with diabetes. Fast-acting insulin analogs have been found to safely and effectively manage blood sugar after meals better than standard human insulin, with fewer episodes of low blood sugar. Similarly, long-acting analogs avoid the pronounced peaks typical of NPH insulin and are associated with fewer nighttime hypoglycemic episodes. This review highlights target blood glucose levels during pregnancy, how to use insulin for GDM, and the appropriate dosing for insulin and its analogs. It's crucial for women's healthcare providers to thoroughly understand insulin management in GDM to deliver complete care for those whose pregnancies are complicated by diabetes, aiming to shift the region's reputation from having a high prevalence of diabetes to being a leader in diabetes care

Keywords : GDM, Insulin, Pregnancy, Analogs, Lispro, Detemir, Diabetes

Introduction:

While dietary and lifestyle adjustments can adequately control blood sugar in many women with GDM, a significant number ultimately require pharmacological therapy—most commonly insulin—to achieve stringent glycemic goals and minimize adverse outcomes. Rapid developments in insulin therapy, including modern analogs, have revolutionized management, offering enhanced physiological control and fewer side effects such as hypoglycemia.

Epidemiology and Clinical Burden

The global landscape of hyperglycemia in pregnancy is striking. By 2013, **16.9% of pregnancies worldwide**—over **21 million births**—were exposed to abnormal maternal blood glucose, and GDM accounted for nearly **84%** of these cases. India leads with a **27.5% prevalence** and approximately **5.7 million women** affected, followed by China at 1.2 million and the USA at 350,000. These numbers underscore the urgency and magnitude of GDM as a public health priority, especially in South East Asia where the prevalence is highest (25%).

Pathophysiology and Rationale for Management

The management rationale is grounded in the **Pedersen hypothesis**: fetal overgrowth (macrosomia) and associated complications stem from **fetal hyperinsulinemia**, itself triggered by maternal hyperglycaemia. Because glucose easily traverses the placenta while insulin does not, the foetus responds to elevated maternal glucose by producing more insulin, resulting in abnormal growth and additional metabolic effects. Thus, **tight maternal glycaemic control** is the mainstay of intervention to prevent diabetic fetopathy.

Considering Glycemic Targets

Historical and Current Standards

International consensus, as reiterated in major workshops, proposes:

- **Fasting glucose:** ≤96 mg/dl (5.3 mmol/l)
- **2-hour post-meal (postprandial):** ≤120 mg/dl (6.7 mmol/l)jogi

Yet, these thresholds are drawn from older population data and may not perfectly mirror truly "normal" pregnancy glycemia, which, according to a comprehensive review of non-diabetic pregnant women, may average:

- 71 ± 8 mg/dl fasting
- 109 ± 13 mg/dl at 1 hour postprandial

- 99 ± 10 mg/dl at 2 hours postprandial

The **Hernandez et al.** analysis advocates for even stricter targets—81 mg/dl fasting and 110 mg/dl 2 hours after eating—highlighting a paradox: many women with GDM delivering macrosomic infants have glucose within current "normal" ranges, possibly implicating non-glucose nutrients or the need to re-define maternal glycemic norms.

Balancing Risks: Hyper- vs. Hypoglycemia

Management is a balancing act. **Overt hyperglycemia** elevates the risk of having large-for-gestational-age (LGA) infants, while aggressive lowering may increase **small-for-gestational-age (SGA)** risks from recurrent maternal hypoglycemia. Presently, the Indian GDM guidelines recommend:

- **Fasting:** ~90 mg/dl
- **2-hour postprandial:** ~120 mg/dl
- **Mean daily glucose:** 105–110 mg/dl
- **HbA1c goal for pre-existing diabetes:** <6%

When is Pharmacologic Therapy Needed?

Most women diagnosed with GDM can initially be managed through a structured **medical nutrition therapy (MNT)** plan. However, if target glycemia is not reached within short intervals (often 2 weeks), insulin is introduced. Although the American College of Obstetricians and Gynecologists (ACOG) recently stated that oral agents may be equivalently effective for GDM, **insulin remains the only FDA-approved option** and is preferred for pregnant women not achieving goals with diet alone or who have more severe hyperglycemia.

Predicting the Need for Insulin

Efforts have been made to predict which GDM patients will require insulin, using combinations of baseline clinical and laboratory predictors such as glycemia at diagnosis, family history, and timing. However, these predictors account for only about **9% of risk**, with actual insulin needs fluctuating unpredictably through gestation for most women. Therefore, **personalized and ongoing monitoring** is necessary for all, reinforcing the need for individualized care.

Evolution of Insulin Therapy

The Historical Context

Before the discovery and clinical introduction of insulin in 1921, fewer than 100 reported pregnancies in diabetic women existed, marked by catastrophic outcomes: **90% infant mortality and 30% maternal mortality**. Improvements in glucose monitoring and control since the 1980s have dramatically reduced perinatal risk to that of the general population.

Types of Insulin: Traditional vs. Modern Analogs

Regular Human Insulin (RHI) and NPH

- **RHI:** Onset is delayed by molecular self-association into hexamers, leading to slow absorption and delayed peak. This mismatch with physiological insulin requirements can result in **pre-meal hyperglycemia** and subsequent **preprandial hypoglycemia**.
- **NPH:** An intermediate-acting formulation, with a duration of action of 16–18 hours. Its pharmacokinetics (unpredictable peak, need for resuspension) can result in **nighttime hypoglycemia** and dosing inaccuracies.

Summary Table: Traditional Insulin Kinetics

Insulin	Time to Peak	Duration (approx)	Common Issues
RHI	2–4h	6–8h	Late onset, hypo risk
NPH	4–8h	16–18h	No true basal, nocturnal hypo risk

Insulin Analogs: Rapid-Acting and Long-Acting

The advent of **insulin analogs**, with minor amino acid substitutions or chemical modifications, overcomes many of these limitations:

- **Rapid-Acting Analogs (RAIAs):** Insulin lispro and aspart dissociate quickly upon injection, closely mimicking the sharp rise in insulin normally seen with meals. They can be dosed precisely before meals, control postprandial excursions more effectively, and carry a lower risk of hypoglycemia.
- **Long-Acting Analogs:** Insulin detemir (and, less commonly in pregnancy, glargine) provides smooth, 24-hour basal coverage with less variability and fewer nocturnal hypoglycemic episodes.

Mechanisms and Clinical Evidence for Analogs

Insulin Aspart

Substitutes proline at B28 with aspartic acid, allowing faster monomer formation and thus more rapid onset (peak: 30–70 minutes; duration: 2–4 hours). In randomized controlled trials, aspart showed **equivalent safety and efficacy** to RHI in pregnancy.

Insulin Lispro

By inverting two amino acids (lysine and proline), lispro also rapidly dissociates to monomers post-injection. Its clinical profile: peak at 1 hour, duration 2–4 hours. In comparative studies, lispro demonstrated **fewer hypoglycemic episodes** and better post-meal glucose control without increased adverse pregnancy outcomes.

Insulin Glulisine

Pharmacologically similar to aspart and lispro, but **not currently approved for pregnancy** due to insufficient data.

Insulin Glargine A long-acting analog, with a flat 24-hour action curve. While some case–control data suggest no increased adverse outcomes versus NPH, glargine is **not FDA-approved for pregnancy** pending more robust trial evidence.

Insulin Detemir

Approved in 2012 for pregnancy use. Its unique acylation leads to albumin binding, blunting the peak and providing sustained basal activity. Detemir matches or exceeds NPH for glycemic stability, with less nocturnal hypoglycemia and no increased risk observed in pregnancy trials.

Practical Insulin Regimens

Basal–Bolus Approach

The **physiological model** is to provide basal insulin to limit hepatic glucose production and rapid-acting ("bolus") insulin before meals to control prandial glucose surges. The **basal–bolus regimen** typically involves **at least four injections** daily: one basal (NPH or detemir) and three rapid-acting prior to each meal. Individual doses are titrated based on self-monitored blood glucose, with frequent adjustment necessary during the dynamic phases of pregnancy.

Dose Calculations and Adjustments

Insulin requirements **vary by pregnancy stage**:

- **Pre-conception:** ~0.8 units/kg/day
- **First trimester:** ~0.7 units/kg/day (may need dose reduction to avoid lows)
- **Second trimester:** Returns to ~0.8 units/kg/day
- **Third trimester:** Peaks at 0.9–1.0 units/kg/day due to placental hormone-mediated insulin resistance

Special populations (morbid obesity or twin gestation) may require **up to 2 units/kg**.

NPH/RHI Regimen Example:

- Morning: 2/3 of total daily dose in a 2:1 NPH:RHI ratio; remaining 1/3 in evening as 1:1 NPH:RHI.

Aspart/Lispro + NPH/Detemir Regimen:

- NPH/Detemir provides basal coverage (given as 2/3 in the AM, 1/3 at bedtime for NPH; or 40–50% of total as detemir at bedtime).
- RAIAs are split into three and dosed before each major meal.

Premixed Analog Formulations

To minimize injection burden, **premix analogs** combine rapid-acting and basal components (e.g., biphasic aspart 30/70), allowing twice-daily dosing that is more patient-friendly, though marginally less flexible. In trials, premix aspart achieved glycemic targets with lower overall doses and comparable perinatal outcomes compared with human premix insulin.

Premix Regimen Example:

- Two daily injections covering both basal and prandial needs.

Self-Monitoring and Safety

Daily glucose monitoring (at least 4–6 times per-day) is mandatory to fine-tune dosage and detect excursions, especially hypoglycemia. Most hypoglycemia risk occurs overnight or between meals. Management of mild lows involves protein–carbohydrate snacks (10–20g each); persistent or frequent hypoglycemia mandates immediate dose reduction.

Visuals and Tables from the Article

Key Visual Table: Insulin Types and Clinical Use

Insulin	Pregnancy Approval	Mechanism	Onset/Peak/Duration	Unique Features
RHI/NPH	Yes	Traditional	1–2h/4–8h/6–18h	Less physiologic, ↑hypo risk
Lispro/Aspart	Yes	Rapid-acting	10–30m/1h/2–4h	Fast, less crossing placenta
Glulisine	No	Rapid-acting	20m/1h/2–4h	Not for pregnancy
Glargine	No	Long-acting	1.5h/None/24h	Not FDA-approved for pregnancy
Detemir	Yes (Cat B)	Long-acting	1–2h/Flat/24h	Stable, low nocturnal hypoglycemia

Dosing Dynamics Over Pregnancy (Adapted From Article)

As pregnancy advances:

- Early: Lower requirements due to hormonal drop (down to 0.7 units/kg)
- Second/third trimesters: Increasing need (up to 1.0 units/kg or more)
- Post-delivery: Dramatic decrease with loss of placental hormones

Insulin Effect and Glycemic Target Rationale

Textual *Visual:*

If postprandial targets are set near non-diabetic levels (110 mg/dl at 2 hours post-eating), LGA risk drops; if fasting is maintained around 90 mg/dl, SGA is usually avoided, provided there is careful monitoring for hypoglycemia in the mother and fetus.

Clinical Evidence and Guideline Summary

- **Lispro and aspart** are **consistently favored** over RHI in pregnancy for better post-meal control and avoidance of hypoglycemia.
- **Detemir** is preferred for basal coverage due to more predictable absorption and less nocturnal hypoglycemia compared with NPH.
- **Premix analogs** are valid alternatives when complexity or compliance precludes basal-bolus regimens.

Conclusion:

Insulin remains the **gold standard therapy** when dietary measures alone are insufficient in GDM. Rapid-acting analogs (aspart and lispro) and long-acting detemir offer reliable efficacy and safety in pregnancy. Premixed regimens provide simplified alternatives for women struggling with multiple injections. Individualized therapy, guided by glucose monitoring and pregnancy progression, is key to optimizing outcomes for both mother and baby.Management of diabetic pregnancy is fundamentally about maintaining **maternal glycemia near normal** while balancing risks and ensuring maternal and fetal safety. Rapid-acting and long-acting insulin analogs now provide treatment options that more closely mimic physiologic needs, reduce hypoglycemia, and improve patient satisfaction. Yet, all regimens must be **carefully individualized**, reflecting ongoing blood glucose monitoring, pregnancy stage, maternal body habitus, and evolving clinical circumstances. Optimal management of gestational diabetes mellitus (GDM) is critical to reducing risks for both mother and child.

REFERENCES:

1. Guariguata L, Linnenkamp U, Beagley J, et al. Global estimates of the prevalence of hyperglycaemia in pregnancy for 2013 for the IDF Diabetes Atlas. Diabetes Res Clin Pract. 2013;. doi: 10.1016/j.diabres.2013.11.003.
2. Pedersen J. Diabetes mellitus and pregnancy: present status of the hyperglycaemia–hyperinsulinism theory and the weight of the newborn baby. Postgrad Med J. 1971;(Suppl):66–67.
3. Magon N, Seshiah V. Gestational diabetes mellitus: noninsulin management. Indian J Endocr Metab. 2011;15:284–93.
4. Hernandez TL, Friedman JE, Van Pelt RE, et al. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care. 2011;34:1660–8.
5. Metzger BE, Lowe LP, Dyer AR, et al. HAPO study cooperative research group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.
6. Crowther CA, Hiller JE, Moss JR, et al. Australian Carbohydrate Intolerance Study in pregnant women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352:2477–86.
7. Landon MB, Spong CY, Thom E, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361:1339–48.
8. Langer O. Maternal glycemic criteria for insulin therapy in GDM. Diabetes Care. 1998;21(2):B91–8.
9. Diagnosis and Management of GDM: Indian Guidelines. Association of Physicians of India. Medicine Update 2013; Vol 13: Chapter 55.
10. Gestational diabetes mellitus. Practice Bulletin No. 137. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2013;122:406–16
11. Pertot T, Molyneaux L, Tan K, et al. Can common clinical parameters be used to identify patients who will need insulin treatment in gestational diabetes mellitus? Diabetes Care. 2011; 34(10):2214–6.
12. Magon N, Chauhan M. Pregnancy in type 1 diabetes mellitus: how special are special issues? N Am J Med Sci. 2012;4:250–6.

13. Lambert K, Holt RI. The use of insulin analogues in pregnancy. Diabetes Obes Metab. 2013;15(10):888–900.

14. Durnwald CP. Insulin analogues in the treatment of gestational diabetes mellitus. Clin Obstet Gynecol. 2013;56(4):816–26.

15. Singh C, Jovanovic L. Insulin analogues in the treatment of diabetes in pregnancy. Obstet Gynecol Clin N Am. 2007; 34:275–91.

16. Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30(4):771–6.

17. Zhou L, Fan L. Efficacy and safety of insulin aspart versus regular human insulin for women with gestational diabetes mellitus. Zhonghua Yi Xue Za Zhi. 2012;92(19):1334–6.

18. Heller S, Damm P, Mersebach H, et al. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study. Diabetes Care. 2010;33(3):473–7.

19. Lloyd A, Townsend C, Munro V, et al. Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK. Curr Med Res Opin. 2009; 25(3):599–605.

20. Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol. 2008;98(2):186e.1–7.

21. Pettitt DJ, Ospina P, Howard C, et al. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med. 2007;24(10):1129–35.

22. Di Cianni G, Torlone E, Lencioni C, et al. Perinatal outcomes associated with the use of glargine during pregnancy. Diabet Med. 2008;25(8):993–6.

23. Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003; 26(1):183–6.

24. Lindholm A, Jensen LB, Home PD, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25(5):876–82.

25. Durnwald CP, Landon MB. A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy. J Matern Fetal Neonataled. 2008;21(5):309–13.